Understanding the Changing needs for Combination Products and Digital Health

09:15 - 09:50

Lilly.png

 

Over the past several years, development of novel subcutaneous delivery technologies has undergone significant growth fuelled to a great extent by the increasing importance of protein based combination products as treatments for acute and chronic diseases.  Likewise, investments in digital health through the integration of connectivity with drug delivery has continued to grow in the med tech and pharma industries. While the emerging landscape has great potential to yield new compelling solutions for patients and caregivers, it does present the drug delivery and device community with some unique challenges.  A number of these challenges and potential areas of opportunity for future development will be highlighted, as well as critical enablers that drive and integrate continued evolution and rapid innovation in these important areas.

Andrew M. Ratz, Senior Director, Delivery, Device and Connected Solutions, Eli Lilly and Company